Stocks Health care CTOR
NASDAQ · Health careCitius Oncology, Inc. (CTOR)
It posted a net loss of $46.1M. At June 30, 2026 it held $16.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Citius Oncology, Inc.
- Net worth
- Citius Oncology, Inc. has a market value (market cap) of $51.1M at the latest share price, and shareholders' equity of $40.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $5.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Citius Oncology, Inc.'s next report is expected around December 22, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Citius Oncology, Inc. does
Citius Oncology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CTOR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$24.8M | -$0.34 | n/a |
| 2024 | n/a | -$21.1M | -$0.31 | n/a |
| 2023 | n/a | $2.4M | $0.27 | n/a |
| 2024 | n/a | -$12.7M | -$0.19 | n/a |
| 2022 | n/a | $380.8K | $0.12 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Citius Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026
- August 26, 2026
- August 26, 2026Proxy statement DEF 14A
- August 14, 2026
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 5, 2026Other event 8-K
- June 4, 2026Activist stake changed SCHEDULE 13D/A
- June 1, 2026Other event 8-K
Insider trades
What the people running Citius Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CTOR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 19 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Armistice Capital, LLC | 8,705,589 | -483,266 |
| Bank of America Corp | 3,835,160 | 0 |
| Vanguard Capital Management LLC | 546,325 | +11,501 |
| UBS Group AG | 334,619 | +297,779 |
| Geode Capital Management, LLC | 245,407 | -19,326 |
| Vanguard Fiduciary Trust Co | 121,910 | 0 |
| IFP Advisors, Inc | 107,424 | 0 |
| Citadel Advisors LLC | 90,586 | new |
| Northern Trust Corp | 45,746 | 0 |
| State Street Corp | 42,900 | 0 |
| XTX Topco Ltd | 20,638 | new |
| Tower Research Capital LLC (TRC) | 13,816 | new |
| Arkadios Wealth Advisors | 11,666 | 0 |
| Osaic Holdings, Inc. | 1,000 | -9,125 |
| Wells Fargo & Company | 500 | new |
| Barclays PLC | 90 | new |
| Morgan Stanley | 23 | new |
| Virtu Financial LLC | 21,877 | new |
| Caitong International Asset Management Co., Ltd | 1 | 0 |
Insiders
10 insiders reported holding 6,021,228 shares in total, about $3.3M at the last price.
| Holder | Shares |
|---|---|
| Mazur Leonard LChief Executive Officer, Director | 1,700,000 |
| Holubiak Myron ZSecretary, Director | 850,000 |
| Bartushak JaimeChief Financial Officer | 825,000 |
| Czuczman MyronChief Medical Officer | 825,000 |
| Mayersohn Joel DavidDirector | 321,228 |
| Smith Robert JosephDirector | 300,000 |
| Mcgrath Dennis MDirector | 300,000 |
| Dutia Suren GDirector | 300,000 |
| Webb CarolDirector | 300,000 |
| Holuka Eugene MyronDirector | 300,000 |
Questions about CTOR
What does Citius Oncology, Inc. do?
Citius Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as CTOR. Its shares trade on NASDAQ under the ticker CTOR.
What is Citius Oncology, Inc.'s net worth?
Citius Oncology, Inc. has a market value (market cap) of $51.1M at the latest share price, and shareholders' equity of $40.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Citius Oncology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $46.1M.
When did Citius Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from September 29, 2026.
When is Citius Oncology, Inc.'s next earnings report?
Citius Oncology, Inc.'s next report is expected around December 22, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CTOR with
Follow CTOR
Get an email when Citius Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Citius Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.